Influence of Aldehyde Dehydrogenase Inhibition on Stemness of Endometrial Cancer Stem Cells
Authors:
- Beatriz SerambequeBSBeatriz Serambeque
- Catarina MestreCMCatarina Mestre
- Gabriela Correia-BarrosGCGabriela Correia-Barros
- Ricardo TeixoRTRicardo Teixo
- Carlos Miguel MartoCMCarlos Miguel Marto
- Ana Cristina GonçalvesAGAna Cristina Gonçalves
- Francisco CarameloFCFrancisco Caramelo
- Isabel SilvaISIsabel Silva
- Artur PaivaAPArtur Paiva
- Hans C. BeckHBHans C. Beck
- Ana Sofia CarvalhoACAna Sofia Carvalho
- Maria Filomena BotelhoMaria Filomena Botelho
Open Access
Abstract
Endometrial cancer is one of the most common gynaecological malignancies. Although often diagnosed at an early stage, there is a subset of patients with recurrent and metastatic disease for whom current treatments are not effective. Cancer stem cells (CSCs) play a pivotal role in triggering tumorigenesis, disease progression, recurrence, and metastasis, as high aldehyde dehydrogenase (ALDH) activity is associated with invasiveness and chemotherapy resistance. Therefore, this study aimed to evaluate the effects of ALDH inhibition in endometrial CSCs. ECC-1 and RL95-2 cells were submitted to a sphere-forming protocol to obtain endometrial CSCs. ALDH inhibition was evaluated through ALDH activity and expression, sphere-forming capacity, self-renewal, projection area, and CD133, CD44, CD24, and P53 expression. A mass spectrometry-based proteomic study was performed to determine the proteomic profile of endometrial cancer cells upon N,N-diethylaminobenzaldehyde (DEAB). DEAB reduced ALDH activity and expression, along with a significant decrease in sphere-forming capacity and projection area, with increased CD133 expression. Additionally, DEAB modulated P53 expression. Endometrial cancer cells display a distinct proteomic profile upon DEAB, sharing 75 up-regulated and 30 down-regulated proteins. In conclusion, DEAB inhibits ALDH activity and expression, influencing endometrial CSC phenotype. Furthermore, ALDH18A1, SdhA, and UBAP2L should be explored as novel molecular targets for endometrial cancer.Keywords
Funding Information
- Foundation for Science and Technology (FCT), Portugal (UIDB/04539/2020, UIDP/04539/2020, LA/P/0058/2020, 02/2017, 07/2018, SFRH/BD/116794/2016)
- Associated Laboratory (UIDB/04539/2020, UIDP/04539/2020, LA/P/0058/2020, 02/2017, 07/2018, SFRH/BD/116794/2016)
- CIMAGO (UIDB/04539/2020, UIDP/04539/2020, LA/P/0058/2020, 02/2017, 07/2018, SFRH/BD/116794/2016)
- Sociedade Portuguesa de Ginecologia/Bayer (UIDB/04539/2020, UIDP/04539/2020, LA/P/0058/2020, 02/2017, 07/2018, SFRH/BD/116794/2016)
- the European Social Fund (FSE) (UIDB/04539/2020, UIDP/04539/2020, LA/P/0058/2020, 02/2017, 07/2018, SFRH/BD/116794/2016)
This publication has 66 references indexed in Scilit:
- CD133 as a regulator of cancer metastasis through the cancer stem cellsThe International Journal of Biochemistry & Cell Biology, 2019
- Endometrial Cancer Spheres Show Cancer Stem Cells Phenotype and Preference for Oxidative MetabolismPathology and Oncology Research, 2018
- Mammospheres of hormonal receptor positive breast cancer diverge to triple-negative phenotypeThe Breast, 2018
- Preliminary identification of endometrial cancer stem cells in vitro and in vivoBiochemical and Biophysical Research Communications, 2017
- Inhibition of ALDH1A1 activity decreases expression of drug transporters and reduces chemotherapy resistance in ovarian cancer cell linesThe International Journal of Biochemistry & Cell Biology, 2016
- Clinical translation for endometrial cancer stem cells hypothesisCancer and Metastasis Reviews, 2015
- Inhibition of aldehyde dehydrogenase (ALDH) activity reduces chemotherapy and radiation resistance of stem-like ALDHhiCD44+ human breast cancer cellsBreast Cancer Research and Treatment, 2011
- The Role of Human Aldehyde Dehydrogenase in Normal and Cancer Stem CellsStem Cell Reviews and Reports, 2010
- The Human Protein Atlas—a tool for pathologyThe Journal of Pathology, 2008
- p53 Interference and Growth Inhibition in p53-Mutant and Overexpressing Endometrial Cancer Cell LinesGynecologic Oncology, 1997